Kaskela Law LLC is investigating the adequacy of the shareholder buyout offer made to STAAR Surgical Company (NASDAQ: STAA) (“STAAR” or the “Company”) investors to determine whether the proposal is fair and provides sufficient monetary consideration for STAA shares.  Following the proposed transaction, STAAR shares will no longer be publicly traded.

On August 5, 2025, STAAR announced that it had agreed to be acquired by Alcon at a price of $28.00 per share, which is significantly lower than the Company’s 52-week high price of $38.60 per share.

The investigation so far has discovered that the transaction appears to have significant conflicts of interest, thus making the sales process and consideration unfair to the Company’s shareholders.  Additionally, STAAR’s largest shareholder has publicly stated that its “serious concerns about the fairness and integrity of the sales process, in addition to the insufficient merger consideration, lead us to believe that the acquisition is not in the best interest of STAAR’s shareholders.”

STAAR shareholders who believe the buyout price is too low are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their no-cost legal rights and options at (484) 229 – 0750, or by completing the form on this page.

CONTACT:

KASKELA LAW LLC
D. Seamus Kaskela, Esq.
([email protected])
Adrienne Bell, Esq.
([email protected])
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 – 1740
(484) 229 – 0750